On a disclosed basis, revenue rose from KRW 69.1 billion in 2022 to KRW 79.2 billion in 2023 and KRW 82.6 billion in 2024, then fell 11.8% to KRW 72.8 billion in 2025. Within 2022 to 2025, 2024 was the largest year and 2022 the smallest.
Operating profit peaked at KRW 40.4 billion in 2023, then fell to KRW 34.2 billion in 2024 and KRW 20.4 billion in 2025, two consecutive years of decline, and the operating margin slid from 48.7% in 2022 and 51.0% in 2023 to 41.5% in 2024 and 28.0% in 2025.
The company attributed the 2025 revenue decline to the renewal of its core product lines and a reallocation of supply regions to improve profitability.
The same year, a conservative bad-debt provision reflecting Middle East tensions and foreign-currency valuation gains and losses tied to a weaker exchange rate weighed further on earnings.
As a result, net profit attributable to controlling shareholders fell 37.8% to KRW 20.1 billion in 2025, and total net profit including non-controlling interests was also KRW 20.1 billion. For the 2024 operating profit decline, the company pointed mainly to higher R&D spending.
Quarterly, Q4 2025 swung to an operating loss of KRW 7.07 billion and a net loss attributable to controlling shareholders of KRW 3.28 billion.
Q1 2026 returned to profit with KRW 22.7 billion in revenue, KRW 10.2 billion in operating profit and KRW 11.7 billion in controlling-shareholder net profit, the peak of the period shown.
Q2 2026 revenue was KRW 18.8 billion with operating profit of KRW 5.24 billion, and Q3 2026 revenue was KRW 18.4 billion with operating profit of KRW 7.19 billion. Q3 operating profit rose 37.3% from the prior quarter but fell 27.1% year on year.
Controlling-shareholder net profit was KRW 648 million in Q3, down 93.6% year on year, and the last four quarters combined total KRW 13.4 billion. In its Q2 announcement, the company had flagged deferred European sales and a bad-debt provision reversal for Q3, yet Q3 revenue was 2.2% lower than in the prior quarter.